Esophagitis, treatment-related toxicity in non-small cell lung cancer

Reviews on Recent Clinical Trials

Volumn 7, Issue 1, 2012, Pages 31-35

  Bar Ad, Voichita ^a   Ohri, Nitin ^a   Werner Wasik, Maria ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Esophagitis; Non Small Cell Lung Cancer; Radiotherapy

Indexed keywords

CANCER PATIENT; DOSIMETRY; ESOPHAGITIS; ESOPHAGUS INJURY; HUMAN; IMMOBILIZATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; RISK ASSESSMENT;

CARCINOMA, NON-SMALL-CELL LUNG; CAUSALITY; ESOPHAGITIS; HUMANS; LUNG NEOPLASMS; RADIATION DOSAGE; RADIATION INJURIES;

EID: 84857385004     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488712799363235     Document Type: Review

References (46)

1. Werner-Wasik M, Paulus R, Curran WJ Jr, Byhardt R. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer: Analysis of the Radiation Therapy Oncology Group (RTOG) database. Clin Lung Cancer 2011; 12(4): 245-51.
2. Cox JD, Pajak TF, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: Analysis of 1244 cases from 3 RTOG trials. Int J Radiat Oncol Biol Phys 1993; 27: 493-8.
3. Werner-Wasik M, Pequignot E, Leeper D, Hauck W and Curran W. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: A multivariate analysis of patients with lung cancer treated with non-operative therapy. Int J Radiat Oncol Biol Phys 2000; 48: 689-96.
4. Werner-Wasik M, Paulus R, Curran WJ Jr, Byhardt R. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small cell lung cancer: Analysis of the Radiation Therapy Oncology Group (RTOG) database. Clin Lung Cancer 2011; 12(4): 245-51.
5. Saunders MI, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomized multicenter trial. Lancet 1997; 350: 161-5.
6. Vokes EE, Herndon JE 2nd, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 2002; 20(20): 4191-8.
7. Trodella L, Granone P, Valente S, et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small cell lung cancer. J Clin Oncol 2002; 20(3): 804-10.
8. D'Angelillo RM, Trodella L, Ciresa M, et al. Multimodality treat ment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy. J Thorac Oncol 2009; 4(12): 1517-23.
9. Trodella L, De Marinis F, D'Angelillo RM, et al. Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer. Lung Cancer 2006; 54(3): 331-8.
10. Ball D, Bishop J, Smith J, O'Brien P, Davis S, Ryan G, Olver I, Toner G, Walker Q, Joseph D. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999; 52(2): 129-36.
11. Ahn S, Kahn D, Zhou S, et al. Dosimetric and clinical predictors for radiation-induced esophageal injury. Int J Radiat Oncol Biol Phys 2005; 61: 335-47.
12. Patel AB, Edelman MJ, Kwork Y, Krasna MJ, Suntharalingam M. Predictors of acute esophagitis in patients with non small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 2004; 60: 1106-12.
13. Langer C, Hsu C, Curran W, et al. Do elderly patients with locally advanced non-small cell lung cancer benefit from combined modality treatment? A secondary analysis of RTOG 94-10. Int J Radiat Oncol Biol Phys 2001; 51(1 Suppl): 20-1.
14. Maguire PD, Sibley GS, Zhou SM, et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys 1999; 45(1): 97-103.
15. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002; 54: 348-56.
16. Singh AK, Lockett MA and Bradley JD. Predictors of radiationinduced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003; 55: 337-4.
17. Bradley J, Deasy JO, Bentzen S, El-Naqa I. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. Int J Radiat Oncol Biol Phys 2004; 58: 1106-13.
18. Kim TH, Cho KH, Pyo HR, et al. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2005; 64(4): 995-1002.
19. Takeda K, Nemoto K, Saito H, Ogawa Y, Takai Y, Yamada S. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2005; 62: 626-9.
20. Belderbos J, Heemsbergen W, Hoogeman M, Pengel K, Rossi M, Lebesque J. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. Radiother Oncol 2005; 75: 157-64.
21. Chapet O, Kong FM, Lee JS, Hayman JA, Ten Haken RK. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 2005; 77: 176-81.
22. Qiao WB, Zhao YH, Zhao YB, Wang RZ. Clinical and dosimetric factors of radiation-induced esophageal injury: Radiation-induced esophageal toxicity. World J Gastroenterol 2005; 11: 2626-9.
23. Wei X, Liu HH, Tucker SL, et al. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 100-7.
24. Rodriguez N, Algara M, Foro, P, et al. Predictors of acute esophagitis in lung cancer patients treated with concurrent threedimensional conformal radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2005; 73(3): 810-7.
25. Werner-Wasik M, Yorke E, Deasy J, Nam J, Marks LB. Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys 2010; 76(3 Suppl): S86-93.
26. Kahn D, Zhou S, Ahn SJ, et al. "Anatomically-correct" dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics. Int J Radiat Oncol Biol Phys 2005; 62(3): 645-51.
27. Dieleman EMT, Sesan S, Vincent A, Lagerwaard FJ, Slotman BJ, van Sornsen de Koste JR. Four-dimensional computed tomography analysis of esophageal mobility during normal respiration. Int J Radiat Oncol Biol Phys 2007; 67: 775-80.
28. Fletcher G. Clinical dose-response curves of human malignant epithelial tumors. Br J Radiol 1973; 46: 1.
29. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose escalation study using three-dimensional conformal radiation therapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 318-28.
30. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010; 303: 1070-6.
31. Song SY, Choi W, Shin SS, et al. Fractionated stereotactic body radiation for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 2009; 66(1): 89-93.
32. Milano MT, Chen U, Katz AW, Philip A, Schell MC, Okunieff P. Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy. Radiother Oncol 2009; 91(3): 301-6.
33. Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 72(4): 967-71.
34. Choi GB, Shin JH, Song HY, et al. Fluoroscopically guided balloon dilation for patients with esophageal stricture after radiation treatment. J Vascular Intervent Radiol 2005; 16(12): 1705-10.
35. Emami B. Three-dimensional conformal radiation therapy in bronchogenic carcinoma. Semin Radiat Oncol 1996; 6: 92-7.
36. Grills IS, Yan D, Martinez AA, Vicini FA, Wong JW, Kestin LL. Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation. Int J Radiat Oncol Biol Phys 2003; 57(3): 875-90.
37. Bradley J, Thorstad W, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 59: 78-86.
38. Schild SE. Elective nodal irradiation (ENI) doesn't appear to provide a clear benefit for patients with unresectable non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2008; 72(2): 311-2.
39. Suit H, Goldberg S, Niemierko A, et al. Proton beams to replace photon beams in radical dose treatments. Acta Oncol 2003; 42(8): 800-8.
40. Chang JY, Komaki R, Bucci MK, et al. Failure patterns and toxicity of concurrent proton therapy and chemotherapy for stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2009-75(3): S446.
41. Brizel DM, Wasserman TH, Henke M, Strnad V, Monnier A, Eschwege F, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-45.
42. Werner-Wasik M, Axelrod SA, Friedland DP, et al. Phase II trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemotherapy. Semin Radiat Oncol 2002; 12 (suppl 1)-34-9.
43. Antonadou D. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer. Semin Radiat Oncol 2002; 12 (suppl 1): 50-8.
44. Komaki R, Lee JS, Milas L, et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 2004; 58(5): 1369-77.
45. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small cell lung cancer receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group Trial 98-01. J Clin Oncol 2005; 23(10): 2145-54.
46. Sarna L, Swann S, Langer C, et al. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 2008; 72(5): 1378-84.